BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001...
...and Qiming Venture Partners USA. Among 37 evaluable living donor kidney transplant recipients who received FCR001...
...immunosuppression treatments and remained off immunosuppression through a median follow-up of five years since transplantation. FCR001...
Items per page:
1 - 1 of 1